



Proven protection at a more affordable price













More information

Your veterinary team is your best source of information for your pet's health, recommending the protection you need based on your pet and location. For more information on Imoxi, visit www.imoxitopical.com.



how the trademarked Twist-N-Go™ cap makes application easy for pet owners.








Proven protection at a more affordable price













Proven protection against the threat of fleas, heartworms and intestinal parasites in a single, easy-to-apply monthly application

Imoxi helps keep your dog healthy all year

You want to keep your dogs healthy and protect them from nasty parasites. It's important to protect your dog from the parasites you can see — but parasites you can't see can be even more dangerous. They can threaten the health of your dog.

Imoxi[™] Topical Solution (imidacloprid + moxidectin) offers a trusted combination of ingredients — now at a lower price

- Protection against fleas, heartworms, intestinal parasites and sarcoptic mange in one monthly application
- Kills fleas through contact no bite necessary
- Long-lasting intestinal parasite coverage is good for your dog and your family
- Excellent option for dogs with food allergies that can't tolerate oral flavorings
- The Twist-N-Go[™] cap makes application easy for pet owners
- ✓ Made in the USA



Fleas

- Fleas are found outdoors and inside and can cause your dog to scratch, chew, bite, lose fur and become restless.
- Fleas you see are only the tip of the iceberg. Their family can infest your home, living in carpets, bedding, furniture and flooring. When looking for their next blood meal, they will bite you and your dog!



Heartworms

- Heartworms are transmitted through infected mosquitoes and cause coughing, sluggishness and difficult breathing; however, some dogs show no signs at all.
- Heartworms can be fatal if left untreated.



Intestinal Parasites

 Intestinal parasites such as roundworms, hookworms and whipworms are everywhere. Your dog may pick them up at

- dog parks, from other dogs, drinking from a public water bowl or pond, or even taking a walk through the neighborhood.
- These worms cause inflammation, anemia, diarrhea and, in some puppies, even death.
- Some intestinal parasites can be a danger to your family! These zoonotic diseases can be transmitted from animals to humans.
 Anyone coming in contact with fecalcontaminated soil is at risk, especially infants, the elderly or those with compromised immune systems.



Sarcoptic Mange

- Also known as scabies, these mites cause severe itchiness and a pimple-like rash.
- Sarcoptic mange is extremely contagious and can be transmitted from animals to humans.

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. Dogs: WARNING: **DO NOT ADMINISTER THIS PRODUCT ORALLY.** For the first 30 minutes after application, ensure that dogs cannot lick the product from application sites on themselves or other treated animals. Children should not come in contact with the application sites for two (2) hours after application. (See Contraindications, Warnings, Human Warnings and Adverse Reactions for more information.) Cats: Do not use on sick, debilitated, or underweight cats. Avoid oral ingestion. For full prescribing information, completely unfold brochure.



Proven protection against the threat of fleas, heartworms and intestinal parasites in a single, easy-to-apply monthly application

Imoxi helps keep your cat healthy all year

You want to keep your cat healthy and protect it from nasty parasites. It's important to protect your cat from the parasites you can see — but parasites you can't see can be even more dangerous. They can threaten the health of your pet.

Imoxi[™] Topical Solution (imidacloprid + moxidectin) offers a trusted combination of ingredients — now at a lower price

- Protection against fleas, heartworms, intestinal parasites and ear mites in one monthly application
- Kills fleas through contact no bite necessary
- Long-lasting intestinal parasite coverage is good for your cat and your family
- Excellent option for cats with food allergies or who dislike oral products
- The Twist-N-Go[™] cap makes application easy for pet owners
- Made in the USA



Fleas

- Fleas are found outdoors and inside and cause your cat to scratch, chew, bite and become restless.
- Fleas you can see are only the tip of the iceberg. Their family can infest your home, living in carpets, bedding, furniture and flooring. When looking for their next blood meal, they will bite you and your cat!



Heartworms

- While most common in dogs, heartworms can be found in cats.
 They are transmitted through infected mosquitoes and cause coughing, sluggishness and difficult breathing.
- Heartworms can be fatal; there is no treatment for heartworms in cats.



Intestinal Parasites

- Intestinal parasites are easy for your cat to find and cause inflammation, anemia, diarrhea and even death in some kittens.
- Some intestinal parasites can be a danger to your family! These zoonotic diseases can be transmitted from animals to humans. Anyone coming in contact with fecal-contaminated soil is at risk, especially infants, the elderly or those with compromised immune systems.



Ear mites

- Ear mites can be picked up from the environment or other pets.
- Signs include shaking of the head, ear scratching, inflammation of the ear canals and large accumulations of earwax.

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. Dogs: WARNING: **DO NOT ADMINISTER THIS PRODUCT ORALLY.** For the first 30 minutes after application, ensure that dogs cannot lick the product from application sites on themselves or other treated animals. Children should not come in contact with the application sites for two (2) hours after application. (See Contraindications, Warnings, Human Warnings and Adverse Reactions for more information.) Cats: Do not use on sick, debilitated, or underweight cats. Avoid oral ingestion. For full prescribing information, completely unfold brochure.

IMOXI™ Topical Solution for Dogs (imidacloprid + moxidectin)

Once-a-month topical solution for the prevention of heartworm disease, the treatment of circulating microfilariae, kills adult fleas, is indicated for the treatment of flea infestations, the treatment and control of sarcoptic mange, as well as the treatment and control of intestinal parasite infections in dogs and puppies that are at least 7 weeks of age and that weigh at least 3 lbs.

DO NOT ADMINISTER THIS PRODUCT ORALLY
 For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals.
 Children should not come in contact with application sites for two (2) hours the confliction.

(See Contraindications, Warnings, Human Warnings, and Adverse Reactions for more information.)

Federal (USA) Law restricts this drug to use by or on the order of a licensed veterinarian.

IMOXI™ Topical Solution for Dogs (10% imidacloprid + 2.5% moxidectin) is a colorless to yellow ready-to-use solution packaged in single dose applicator tubes for topical treatment of doss. The formulation and dosage schedule are designed to provide a minimum of 4.5 mg/lb. (10 mg/kg) imidacloprid and 1.1 mg/lb. (2.5 mg/kg) moxidectin based on body weight.

Imitacloprid is a chloronicotify nitroguandine insecticide. The chemical name for imidacloprid is 1-[(6-Chloro-3-pyridinyl) methyll-N-nitro-2-imidazolidinimine. Moxidectin is a semisynthetic macrocyclic lactone endectocide derived from the actinomycete Streptomycetes cyaneogriseus noncyaneous. The chemical name for moxidectin is [SR, 235, 255(E)]-5-O-Demethyl-28-deoxy-25-(1,3-dimeth)-1-butenyl-6-28-epoxy-23-(methoxyrimino) milbemycin B.

IMOXI™ Topical Solution for Dogs is indicated for the prevention of heartworm disease caused by Dirofilana immitts and the treatment of Dirofilaria immitts circulating microfilariae in heartworm-posi-tive dogs. IMOXI™ Topical Solution for Dogs kills adult fleas and is indicated for the treatment of flea intestations (Ctenocephalides felis). IMOXI™ Topical Solution for Dogs is indicated for the treatment and control of sarcoptic mange caused by Sarcoptes scablei var. canis. IMOXI™ Topical Solution for Dogs is also indicated for the treatment and control of the following intestinal parasites

Intestinal Parasite		Intestinal Stage		
		Adult	Immature Adult	Fourth Stage Larvae
Hookworm	Ancylostoma caninum	Х	Х	Х
Species	Uncinaria stenocephala	Х	Х	Х
Roundworm Species	Toxocara canis	Х		Х
	Toxascaris leonina	Х		
Whipworm	Trichuris vulpis	Х		

CONTRAINDICATIONS:

Do not administer this product orally. (See WARNINGS)

not use this product (containing 2.5% moxidectin) on cats

For the first 30 minutes after application:

Ensure that dogs cannot lick the product from application sites on themselves or othe treated dogs, and separate treated dogs from one another and from other pets to reduce the risk of accidental ingestion.

Ingestion of this product by dogs may cause serious adverse reactions including depression, salivation, dilated pupils, incoordination, panting, and generalized muscle tremors In avermectin sensitive dogs,^a the signs may be more severe and may include coma and

"Some dogs are more sensitive to avermectins due to a mutation in the MDR1 gene. Dogs with this mutation may develop signs of severe avermectin toxicity if they ingest this product. The most common breeds associated with this mutation include Collies and Collie crosses. ^b Although there is no specific antagonist for avermectin toxicity, even severely affected dogs have

completely recovered from avermectin toxicity with intensive veterinary supportive care

HUMAN WARNINGS: Not for human use. Keep out of the reach of children.

Children should not come in contact with application sites for two (2) hours after application. Causes eye irritation. Harmful if swallowed. Do not get in eyes or on clothing. Avoid contact with skin. Exposure to the product has been reported to cause headache; dizziness; and redness, burning, tingling, or numbness of the skin.

Wash hands thoroughly with soap and warm water after handling.

If contact with eyes occurs, hold eyelids open and flush with copious amounts of water for 15 minutes. If eye irritation develops or persists, contact a physician. If swallowed, call poison control center or physician immediately for treatment advice. Have person sip a glass of water if able to swallow. Do not induce vomiting unless told to do so by the poison control center or physician. People with known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the product with caution. In case of allergic reaction, contact a physician. If contact with skin or clothing occurs, take off contaminated clothing. Wash skin immediately with plenty of soap and water. Call a poison control center or physician for treatment advice.

The Safety Data Sheet (SDS) provides additional occupational safety information. For consumer questions call 1-800-835-9496. For a copy of the Safety Data Sheet (SDS) or to report adverse reactions call Vetoquinol USA, Inc. at

PRECAUTIONS:

Do not dispense dose applicator tubes without complete safety and administration information. Use with caution in sick, debilitated, or underweight animals. The safety of IMOXI™ Topical Solution for Dogs has not been established in breeding, pregnant, or lactating dogs. The safe use of IMOXI™ Topical Solution for Dogs has not been established in puppies and dogs less than 7 weeks of age or less than 3 lbs. body weight.

less than at bs. body weight.

Prior to administration of IMOXI™ Topical Solution for Dogs, dogs should be tested for existing heartworm infection. At the discretion of the veterinarian, infected dogs should be treated with an adulticide to remove adult heartworms. The safety of IMOXI™ Topical Solution for Dogs has not been evaluated when administered on the same day as an adulticide. IMOXI™ Topical Solution for Dogs is not effective against adult D. Immilis. Although the number of circulating microfilariae is substantially reduced in most dogs following treatment with IMOXI™ Topical Solution for Dogs, the microfilariae using the scene of the properties of the properti microfilaria count in some heartworm-positive dogs may increase or remain unchanged following treatment with IMOXI™ Topical Solution for Dogs, alone or in a dosing regimen with melarsomine (See ADVERSE REACTIONS and ANIMAL SAFETY – Safety Study in Heartworm-Positive Dogs.)

Heartworm-Negative Dogs
Field Studies: Following treatment with imidacloprid and moxidectin topical solution or an active control, dog owners reported the following post-treatment reactions:

OBSERVATION	imidacloprid and moxidectin topical solution n=128	Active Control n=68
Pruritus	19 dogs (14.8%)	7 dogs (10.3%)
Residue	9 dogs (7.0%)	5 dogs (7.4%)
Medicinal Odor	5 dogs (3.9%)	None observed
Lethargy	1 dog (0.8%)	1 dog (1.5%)
Inappetence	1 dog (0.8%)	1 dog (1.5%)
Hyperactivity	1 dog (0.8%)	None observed

During a field study using 61 dogs with pre-existing flea allergy dermatitis, one (1.6 %) dog experienced localized pruritus immediately after imidacloprid application, and one investigator noted hyperkeratosis at the application site of one dog (1.6 %).

In a field safety and effectiveness study, imidacloprid and moxidectin topical solution was administered to 92 client-owned dogs with sarcopic mange. The dogs ranged in age from 2 months to 12.5 years and ranged in weight from 3 to 231.5 pounds. Adverse reactions in dogs treated with imidacloprid and moxidectin topical solution included hematochezia, diarrhea, vomiting, lethargy, inapoetence, and proderma. Laboratory Effectiveness Studies: One dog in a laboratory effectiveness study experienced

weakness, depression, and unsteadiness between 6 and 9 days after application with imidaclopid and moxidectin topical solution. The signs resolved without intervention by day 10 post-application. The signs in this dog may have been related to peak serum levels of moxidectin, which vary between dogs, and occur between 1 and 21 days after application of imidacloprid and moxidectin topical The following clinical observations also occurred in laboratory effectiveness studies following

The following clinical osservations also occurred in laboratory effectiveness studies following application with imidacloprid and moxidectin topical solution and may be directly attributed to the drug or may be secondary to the intestinal parasite burden or other underlying conditions in the dogs: diarrhea, bloody stools, vontiling, anotexia, lethargy, coughing, coular discharge and nasal discharge. Observations at the application stess included damp, stiff or greasy hair, the appearance of a white deposit on the hair, and mild erythema, which resolved without treatment within 2 to 48 burge. Heartworm-Positive Dogs

Field Study: A 56-day field safety study was conducted in 214 D. immitis heartworm and microfilaria positive dogs with Class 1, 2 or 3 heartworm disease. All dogs received imidacloprid and moxidectin topical solution on Study Days 6 and 28: 108 dogs also received melarsomine dihydrocthoride on Study Days – 14, 14, and 15. All dogs were hospitalized for a minimum of 12 hours following each treatment. Effectiveness against circulating D. immitis microfilariae was > 90 % at five of six sites; however, one site had an effectiveness of 73.3 %. The microfilaria count in some heartworm-positive dogs increased or remained unchanged following treatment with imidacloprid and moxidectin topical solution alone or in a dosing regimen with melarsomine dihydrochloride.

with melarsomine dihydrochloride, the following adverse reactions were observed:					
	Dogs Treated with	Dogs Treated with imidaclopri			

,	•	
Adverse Reaction	Dogs Treated with imidacloprid and moxidectin topical solution n=106	Dogs Treated with imidaclopric and moxidectin topical solution + Melarsomine n=108
Cough	24 (22.6%)	25 (23.1%)
Lethargy	14 (13.2%)	42 (38.9%)
Vomiting	11 (10.4%)	18 (16.7%)
Diarrhea, including hemorrhagic	10 (9.4%)	22 (20.4%)
Inappetence	7 (6.6%)	19 (17.6%)
Dyspnea	6 (5.7%)	10 (9.3%)
Tachypnea	1 (<1%)	7 (6.5%)
Pulmonary Hemorrhage	0	1 (<1%)
Death	0	3 (2.8%)

Three dogs treated with imidacloprid and moxidectin topical solution in a dosing regimen with melarsomine dihydrochloride died of pulmonary embolism from dead and dying heartworms. One dog, treated with imidacloprid and moxidectin topical solution and melarsomine dihydrochloride experienced pulmonary hemorrhage and responded to supportive medical treatment. Following the first treatment with imidacloprid and movidectin topical solution alone, two dogs experienced adverse reactions (outpling, vomiting, and dyspneal) that required hospitalization. In both groups, there were more adverse reactions to imidacloprid and moxidectin topical solution following the first treatment than the second treatment.

To report a suspected adverse reaction, call 1-800-835-9496. Post-Approval Experience:

DOSAGE AND ADMINISTRATION:

for Dogs tubes

The following adverse events are based on post-approval adverse drug experience reporting. Not all adverse reactions are reported to FDA CVM.

adverse reactions are reported to Pro-CVM.

It is not relationship to product exposure using this data. The following adverse events in dogs are listed in decreasing order of reporting frequency, depression/feltargy, veniting, puritus, diarrhea, anorexia, hyperactivity, ataxia, trembling, hypersalivation, application site reactions (alopeda, pruritus, lesions, and erythem), seziunes, and anaphylaxis/anaphylactic reactions (hives, urticaria, facial swelling, edema of the head).

Serious reactions, including neurologic signs and death have been reported when cats have been exposed (orally and topically) to this product. In humans, nausea, numbness or tingling of the mouth/ lips and throat, ocular and dermal irritation

pruritus, headache, vomiting, diarrhea, depression and dyspnea have been reported following exposure to this product. To report suspected adverse drug events, for technical assistance or to obtain a copy of the SDS, contact Vetoquinol USA, Inc. at 1-800-835-9496.


Contact velocition Only, link at 1-volvess-9-93.


For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/ reportanimalae.

The recommended minimum dose is 4.5 mg/lb. (10 mg/kg) imidacloprid and 1.1 mg/lb. (2.5 mg/kg) moxidectin, once a month, by topical administration.

Remove one dose applicator tube from the package. As specified in the table, administer the entire contents of the IMOXI™ Topical Solution for Dogs tube that correctly corresponds with the body

Dog (lbs.)	Volume (mL)	Imidacloprid (mg)	Moxidectin (mg)	
3–9	0.4	40	10	
9.1-20	1.0	100	25	
20.1-55	2.5	250	62.5	
55.1-88	4.0	400	100	
88.1-110 *	5.0	500	125	
* Dogs over 110 lbs. should be treated with the appropriate combination of IMOXI™ Topical Solut				





3. The dog should be standing for application. Position the dispensing tip on the dog's back between the shoulder blades. The dispensing tip of the tube can be used to part the dog's hair until the skin is

eighing 20 lbs. or less, place the tip of the tube on the skin and apply the entire contents directly on the exposed skin at one spot between the shoulder blades. For dogs weighing more than 20 lbs, place the tip of the tube on the skin and apply the entire contents directly on the exposed skin at 3 or 4 spots on the top of the backline from the base of the neck to the upper back in an area inaccessible to licking. Do not apply an amount of solution at any one location that could run off the

Do not let this product get in your dog's mouth or eyes. **Do not allow the dog to lick any of the application sites for 30 minutes.** In households with multiple pets, keep each treated dog separated from other treated dogs and other pets for 30 minutes after application to prevent licking the application sites (See WARNINGS)

Siff hair, a damp appearance of the hair, pink skin, or a slight powdery residue may be observed at the application site on some animals. This is temporary and does not affect the safety and effectiveness of the product.

Shampooing 90 minutes after treatment does not reduce the effectiveness of IMOXI™ Topical Solution for Dogs in the prevention of heartworm disease. Shampooing or water immersion 4 days after treatment will not reduce the effectiveness of IMOXI™ Topical Solution for Dogs in the treatment of flea infestations. However, shampooing as often as once weekly may reduce the effectiveness of the product against fleas.

the product against fleas.

Heartworm Prevention: For prevention of heartworm disease, IMOXI™ Topical Solution for Dogs should be administered at one-month intervals. IMOXI™ Topical Solution for Dogs may be administered year-round or at a minimum should start one month before the first expected exposure to mosquitoes and should continue at monthly intervals until one month after the last exposure to mosquitoes. If a dose is missed and a 30-day interval between doses is exceeded, administer IMOXI™ Topical Solution for Dogs immediately and resume the monthly dosing schedule. When replacing another heartworm prevention program, the first treatment with IMOXI™ Topical Solution for Dogs should be given within one month of the last dose of the former medication.

Treatment of Circulating Microfilaria: For the treatment of circulating D. immilis microfilaria in heartworm-positive dogs, IMOXI™ Topical Solution for Dogs should be administered at one-month intervals. Treatment with an approved adulticid enterapy is recommended because IMOXI™ Topical Solution for Dogs is not effective for the treatment of adult D. immilitary. (See PRECAUTIONS)

(See PRECAUTIONS)
Flea Treatment: For the treatment of flea infestations, IMOXI™ Topical Solution for Dogs should be administered at one-month intervals. If the dog is already infested with fleas when the first dose of IMOXI™ Topical Solution for Dogs is administered, adult fleas on the dog will be killed. However, reinfestation from the emergence of preexisting uppea in the environment may continue to occur for six weeks or longer after treatment is initiated. Dogs treated with imidacloprid, including those with pre-existing flea allergy dermatitis have shown clinical improvement as a direct result of timination of fleas from the dog.

Treatment and Control of Intestinal Nematode Infections: For the treatment and control of intestinal howkown infections caused by Anovlostoma caninum and Uncinaria stenocephala (adults).

intestinal hookworm infections caused by Ancylostoma caninum and Uncinaria stenocephala (adults, immature adults and fourth stage larvae) and roundworm infections caused by Toxocara canis (adults and fourth stage larvae), and Toxacaras feorina (adults), and whipworm infections caused by Trichuris vulpis (adults), IMOXI™ Topical Solution for Dogs should be administered once as a single topical darpol.

Treatment and Control of Sarcoptic Mange: For the treatment and control of sarcoptic mange caused by Sarcoptes scabiel var. canis, IMOXI™ Topical Solution for Dogs should be administered as a single topical dose. A second monthly dose may be administered if necessary.

ANIMAL SAFFTY: Heartworm-Negative Dogs

Field Study: In a controlled, double-masked, field safety study, imidacloprid and moxidectin topical solution was administered to 128 dogs of various breeds, 3 months to 15 years of age, weighing 4 to 157 pounds. Imidacloprid and moxidectin topical solution was used safely in dogs concomitantly receiving ACE inhibitors, anticonvulsants, antihistamines, antimicrobials, chondroprotectants, corticosteroids, immunotherapeutics, MAO inhibitors, NSAIDs, ophthalmic medications, conditionations, minimited symptomic parameters, more minimited sympathonimetics, symbolic estrogens, thyroid hormones, and urinary acidifiers. Owners reported the following signs in their dogs after application of imidacloprid and moxidectin topical solution: pruritus, flaky/greasy residue at the treatment site, medicinal odor, lethargy, inappetence, and

(See ADVERSE REACTIONS)

Dermal Dose Tolerance Study: Imidacloprid and moxidectin topical solution was administered topically to 8-month-old Beagle dogs at IIOX the recommended dose once. One dog showed signs of treatment site irritation after application. Two dogs vomited, one at 6 hours and one at 6 days post-treatment. Increased RBC, hemoglobin, activated partial thromboplastin, and direct bilirubin were observed in the treated group. Dogs in the treated group did not gain as much weight as the

control group.

Oral Safety Study in Beagles: Imidacloprid and moxidectin topical solution was administered once orally at the recommended topical dose to 12 dogs. Six dogs vomited within 1 hour of receiving the test article, 2 of these dogs vomited again at 2 hours, and 1 dog vomited again up to 18 hours post-dosing. One dog exhibited shaking (nervousness) 1 hour post-dosing, Another dog exhibited abnormal neurological signs (circling, alaxia, generalized muscle tremors, and dilated pupils with a slow pupillary light response) starting at 4 hours post-dosing moyn 18 hours post-dosing. Without treatment, this dog was neurologically normal at 24 hours and had a normal appetite by 48 hours post-dosing.

0

Dermal Safety Study in Ivermectin-Sensitive Collies: Imidacloprid and moxidectin topical solution was administered topically at 3 and 5X the recommended dose every 28 days for 3 treatments to Collies which had been prescreened for avermectin sensitivity. No clinical abnormalities were

Oral Safety Study in Ivermectin-Sensitive Collies: Imidacloprid and moxidectin topical solution was administered orally to 5 pre-screened 'vermectin-sensitive Collies. The Collies were asymptomatic after ingesting 10% of the minimum labeled dose. At 40% of the minimum recommended topical dose, 4 of the dogs experienced neurological signs indicative of avermedin toxicity including depression, ataxia, mydriasis, salivation, muscle fasciculation, and coma, and were outhers and the collies were the collies were considered to the

(See CONTRAINDICATIONS)

Heartworm-Positive Dogs

Laboratory Safety Study in Heartworm-Positive Dogs: Imidaclopid and moxidectin topical solution was administered topically at 1 and 5X the recommended dose every 14 days for 3 treatments to dogs with adult heartworm infections and circulating microflaria. At 5X, one dog was observed vomiting three hours after the second treatment. Hypersensitivity reactions were not seen in the 5X treatment group. Microfilaria counts decreased with treatment.

Store at temperatures between 20° C (68 °F) and 25° C (77 °F), avoiding excess heat or cold. HOW SUPPLIED:

6 x 0.4 mL tubes 6 x 1.0 mL tubes 6 x 2.5 mL tubes

vetoquinoL

4250 N. Sylvania Avenue Fort Worth, TX 76137

Approved by FDA under ANADA # 200-615 Made in U.S.A. © 2019 Vetoquinol USA, Inc. Vetoquinol, the Vetoquinol logo, and IMOXI™ Topical Solution for Dogs are registered trademarks of Vetoquinol USA, Inc.









IMOXI™ Topical Solution for Cats (imidacloprid + moxidectin)

Once-a-month topical solution for cats for the prevention of heartworm disease, kills adult fleas, is indicated for the treatment of flea infestations, as well as the treatment and control of ear mite infestations and intestinal parasite infections in cats and kittens 9 weeks of age and older and that

weigh at least 2 lbs. CAUTION:

Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed

IMOXI™ Topical Solution for Cats (10% imidacloprid + 1% moxidectin) is a colorless to yellow ready-to-use solution packaged in single-dose applicator tubes for topical treatment of cats. The formulation and dosage schedule are designed to provide a minimum of 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin based on body weight.

Imidacloprid is a chloronicotinyl nitroguanidine insecticide. The chemical name inidaciopiro is a (1-(6-Chloro-3-pyridiny))methyl)N-nitro-2-imidazolidinimine. Moxidectin is a semisynthetic macrocyclic lactone endectocide derived from the actinomycete *Streptomycetes cyaneogriseus noncyanogenus*. The chemical name of moxidectin is [6R, 23E, 25S(E)]-5-0-Demethyl-28-deoxy-25-(1,3-dimethyl-1-butenyl)-6,28-epoxy-23-(methoxyimino) milbemycin B.

IMOXI™ Topical Solution for Cats is indicated for the prevention of heartworm disease caused by *Dirofilaria immitis*. IMOXI™ Topical Solution for Cats kills adult fleas (*Ctenocephalides felis*) and is indicated for the treatment of flea infestations. IMOXI™ Topical Solution for Cats is also indicated for the treatment and control of ear mite (*Otodectes cynotis*) infestations and the following interface mite (*Otodectes cynotis*) infestations and the

	following intestinal parasites.				
	Intestinal Parasite		Intestinal Stage		
			Adult	Immature Adult	Fourth Stage Larvae
	Hookworm Species	Ancylostoma tubaeforme	Х	Х	Х
	Roundworm Species	Toxocara cati	Х		Х

Do not use on sick, debilitated, or underweight cats (see ADVERSE REACTIONS). Do not use on cats less than 9 weeks of age or less than

2 lbs. body weight. **HUMAN WARNINGS**

Not for human use. Keep out of the reach of children Children should not come in contact with the application site for 30 minutes after application.

Causes eye irritation. Harmful if swallowed. Do not get in eyes or on clothing.

Causes eye irritation. Harmful if swallowed. Do not get in eyes or on clothing. Avoid contact with skin. Exposure to the product has been reported to cause headache; dizziness; and redness, burning, tingling, or numbness of the skin. Wash hands thoroughly with soap and warm water after handling. If contact with eyes occurs, hold eyelids open and flush with copious amounts of water for 15 minutes. If eye irritation develops or persists, contact a physician. If swallowed, call poison control center or physician immediately for treatment advice. Have person sip a glass of water if able to swallow. Do not induce vomiting unless told to do so by the poison control center or physician. People with known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the product with caution. In case of allergic reaction, contact a physician. If contact with skin or clothing occurs, take off contaminated clothing. Wash skin immediately with plenty of soap and water. Call a poison control center or physician for treatment advice.

The Safety Data Sheet (SDS) provides additional occupational safety.

The Safety Data Sheet (SDS) provides additional occupational safety information. To report suspected adverse drug events, for technical assistance or to obtain a copy of the SDS, contact Vetoquinol USA at 1-800-835-9496 or www.vetoquinolusa.com.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

PRECAUTIONS:

ADVERSE REACTIONS:

Do not dispense dose applicator tubes without complete safety and administration information. Avoid oral ingestion. Cats may experience hypersalivation, tremors, vomiting and decreased appetite if IMOXI^{TM} Topical Solution for Cats is inadvertently administered orally or through grooming/licking of the application site.

The safety of IMOXI™ Topical Solution for Cats has not been established in breeding, pregnant, or lactating cats.

The effectiveness of $\mathsf{IMOXI^{TM}}$ Topical Solution for Cats against heartworm infections (D. immitis) after bathing has not been evaluated in cats.

Use of this product in geriatric patients with subclinical conditions has not been adequately studied. Several otherwise healthy, thin geriatric cats experienced prolonged lethargy and sleepiness after using imidacloprid and moxidectin topical solution. (See ADVERSE REACTIONS).

Field Study: Following treatment with imidacloprid and moxidectin topical solution or an active control, cat owners reported the following post-treatment

OBSERVA	TION	Imidacloprid and Moxidectin Topical Solution n=113	Active Control n=38
Lethargy (protracted poorly responsive)	d sleeping,	3 cats* (2.7%)	None observed
Behavioral changes excessive grooming spinning)	(e.g., agitated, , hiding, pacing,	9 cats (8.0%)	1 cat (2.6%)
Discomfort (e.g., so head-shaking)	ratching, rubbing,	5 cats (4.4%)	None observed
Hypersalivation (wit treatment)	hin 1 hour after	3 cats (2.7%)	None observed
Polydipsia		3 cats (2.7%)	None observed
Coughing and gagg	ing	1 cat (0.9%)	None observed

*These three cats were from the same household and included one 13-yr-old cat in good health, one 15-yr-old FIV positive cat in good health, and one 15-yr-old, underweight cat in fair health. Lethargy was noted for 24 to 36 hrs after the first treatment only; one cat was unsteady at 48hrs. These cats were not on other

During another field study, a 16-year-old cat with renal disease slept in the same place without moving for two days following application. (See PRECAUTIONS).

Laboratory Effectiveness Studies: Imidacloprid and moxidectin topical solution was administered at the recommended dose to 215 cats in 20 solution was administered at the recommended dose to 215 dats in 20 effectiveness studies. One random-sourced cat exhibited signs consistent with either moxidectin toxicity or viral respiratory disease and died 26 hours after product application; necropsy findings were inconclusive as to the cause of death. A second cat that became iil 3 days after application of imidacloprid and moxidectin topical solution responded to treatment for respiratory infection and completed the study. A third cat became ill on day 3 and died with signs and

lesions attributable to panleukopenia on day 7 after moxidectin application Post-Approval Experience: The following adverse events are based on post-approval adverse drug experience reporting. Not all adverse reactions are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data. The following adverse events in cats are listed in decreasing order of reporting frequency: hypersalivation, depression/lethargy, application site reactions (alopecia, pruritus, lesions, and erythema), decreased appetite, vomiting, hyperactivity, ataxia, trembling, and behavior disorder (hiding).

In some cases, death has been reported. In humans, ocular and dermal irritation, nausea, numbness or tingling of the mouth and lips, anaphylaxis, pruritus, vomiting, and tongue/taste abnormalities have been reported following exposure to imidacloprid and moxidectin topical

To report suspected adverse drug events, for technical assistance a copy of the SDS, contact Vetoquinol USA at 1-800-835- 9496 or www.vetoquinolusa.com.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

DOSAGE AND ADMINISTRATION:


The recommended minimum dose is 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month, by topical administration. Do not apply to irritated skin.

Remove one dose applicator tube from the package. As specified in the following table, administer the entire contents of the IMOXI™ Topical Solution for Cats tube that correctly corresponds with the body weight of the cat.

Cat (lbs.)	Volume (mL)	Imidacloprid (mg)	Moxidectin (mg)	
2-5	0.23	23	2.3	
5.1-9	0.4	40	4	
9.1-18*	0.8	80	8	


 * Cats over 18 lbs. should be treated with the appropriate combination of IMOXI Topical Solution for Cats tubes.

and effectiveness of the product.



2. While holding the Twist•N•Go™ tube in an upright position, twist dispensing tip clockwise about ½ turn to break the tube's seal. Remove the cap from the tube.

3. Part the hair on the back of the cat's neck at the base of the head, until the



4. Place the tip of the tube on the skin and apply the entire contents directly on the exposed skin. Lift the tube away from the skin before releasing pressure on

Do not get this product in the cat's mouth or eyes or allow the cat to lick the application site for 30 minutes. Treatment at the base of the head will minimize the opportunity for ingestion by grooming. In households with multiple pets, keep animals separated to prevent licking of the application site. Stiff, matted hair or a damp, oily appearance of the hair may be observed at the application site on some cats. This is temporary and does not affect the safety

Heartworm Prevention: For prevention of heartworm disease, IMOXI™ Topical Solution for Cats should be administered at one-month intervals. IMOXI™ Topical Solution for Cats may be administered year-around or at a minimum should start one month before the first expected exposure to mosquitoes and should continue at monthly intervals until one month after the mosquiroes and should continue at montruly intervals until one month after the last exposure to mosquiroes. If a dose is missed and a 30-day interval between doses is exceeded, administer IMOXI™ Topical Solution for Cats immediately and resume the monthly dosing schedule. When replacing another heartworm preventative product in a heartworm prevention program, the first treatment with IMOXI™ Topical Solution for Cats should be given within one month of the last dose of the former medication. At the discretion of the veterinarian, cats

last 0.0se of the former ineucation. At the discretion of the presence of existing heartworm infection before treatment with IMOXITM Topical Solution for Cats. (See ADVERSE REACTIONS – Post-Approval Experience). Flea Treatment: For the treatment of flea infestations, IMOXI™ Topical Solution for Cats should be administered at one-month intervals. If the cat is already infested with fleas when the first dose of IMOXI™ Topical Solution for Cats is administered, adult fleas on the cat will be killed. However, re-infestation from the emergence of pre-existing pupae in the environment may continue to occur for six weeks or longer after treatment is initiated. Cats treated with imidacloprid, including those with pre-existing flea allergy dematitis, have shown clinical improvement as a direct result of elimination of fleas from the Ear Mite Treatment: For the treatment of ear mites (Otodectes cynotis), IMOXI™ Topical Solution for Cats should be administered once as a single topical dose. Monthly use of IMOXI™ Topical Solution for Cats will control any

subsequent ear mite infestations. Intestinal Nematode Treatment: For the treatment and control of intestinal hookworm infections caused by *Ancylostoma tubaeforme* (adults, immature adults and fourth stage larvae) and roundworm infections caused by *Toxocara* cati (adults and fourth stage larvae) IMOXI[™] Topical Solution for Cats should be administered once as a single topical dose.

Studies in Kittens: Imidacloprid and moxidectin topical solution was topically Studies in Kittens: Imidacioprid and moxidectin topical solution was topically applied at 0, 1, 3, and 5X the maximum dose to 48 healthy 9-week-old kittens on days 0, 28, and 56. Lethargy was observed in 1 kitten from the 3X group and 1 from the 5X group on the day after initial treatment; the kitten from the 3X group was also disoriented and ataxic. One kitten from the 3X group had a slow pupillary light response two days after treatment and one had tremors the day pupiling light response two days after treatment and one lad terinors the day after treatment. Hypersalivation was seen in one kitten from the 5X group approximately six hours post-treatment. One kitten from the 3X group was scratching at the treatment site 2 days after treatment. Slight cough was noted in 7 different kittens (2-0X, 2-1X, and 3-5X) during the 13-day period following the first treatment. Histopathology showed granulomatous inflammation at the treatment site in three 1X kittens. Causal relationship to the drug could not be determined. Pulmonary inflammation (1-5X) and lymphoid hyperplasia (2-1X, 4-3X) were seen in treated kittens. In a second study, imidacloprid and moxidectin topical solution was topically applied at 0, 1.7, 5.2 and 8.7X the maximum dose to 48 healthy 9-week-old kittens every two weeks for 6 doses. One kitten in the 8.7X group apparently ingested an unknown amount of the drug and developed the following clinical signs prior to euthanasia: mydriasis, salivation, depression, vomiting, unsteadiness, rapid to slow to difficult breathing, poor pupillary response, generalized tremors, inability to move, and nystagmus. Two kittens in the 5.2X group developed mydriasis, salivation, depression, squinting, and poor appetite. A kitten in the 1.7X group developed

Dose Tolerance Study: Eight healthy juvenile cats were topically dosed with a single application of imidacloprid and moxidectin topical solution at 10 times the recommended dose volume. Mild, transient hypersalivation occurred in two of

Oral Study in Cats: The oral safety of imidacloprid and moxidectin topical solution was tested in case of accidental oral ingestion. The maximum topical dose was orally administered to twelve healthy 9-week-old kittens. Hypersalivation (8 of 12 kittens) and vomiting (12 of 12 kittens) were observed immediately post-treatment. Tremors developed in one kitten within 1 hour, resolving without treatment within the next hour. All 12 kittens were either anorexic or had decreased appetite for at least 1 day following treatment. In 3 kittens, the anorexia or decreased appetite continued into the second week following treatment. There was a post-treatment loss of body weight in treated kittens compared to control kittens in a pilot safety study using kittens vounger. wittens compared to control kittens. In a pilot safety study using kittens younger in age and lighter in weight than allowed by product labeling, an 8-week-old kitten weighing 0.6 kg orally received 2X of the label topical dose (0.46 mL/kg). Immediately after dosing, it vomited, had labored breathing and slight tremors. Within 4 hours, it was normal, but was found dead on day 6. Necropsy could not determine the course of death.

determine the cause of death. Study in Heartworm Positive Cats: Young adult cats were inoculated subcutaneously with third-stage *D. immitis* larvae. At 243-245 days post-infection, immunoserology and echocardiography were performed to identify cats with adult heartworm burdens similar to naturally-acquired infections. Two groups were treated topically with either imidacloprid and moxidectin topical solution at the label dose or placebo, once every 28 days, for Introduced in topical solution at the labert uses or placebor, office every 20 valys, for three consecutive treatments. A third group was treated topically, once, with imidacloprid and moxidectin topical solution at 5X the label dose. Sporadic vomiting and labored breathing related to heartworm burden were observed in the treatment and control groups. There was no difference between treatment groups in the numbers of adult *D. immitis* recovered at study conclusion. No adverse reactions were associated with the topical application of imidacloprid and moxidectin topical solution to experimentally heartworm-infected cats.

STORAGE INFORMATION:

Chara at temperatures between 20°C (68°F) and 25°C (77°F), avoiding excess

HOW SUPPLIED: Applications Per Package 3 x 0.23 mL tubes

6 x 0.8 mL tubes

Approved by FDA under ANADA # 200-638 Made in U.S.A. © 2020 Vetoquinol USA, Inc

Vetoquinol, the Vetoquinol logo, and IMOXI™ Topical Solution for Cats are registered trademarks of Vetoguinol USA, Inc.

R2 - 08/2020

